(Press-News.org)
Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program, and Head of our Models of Cancer Therapies Group, has received a European Research Council (ERC) Advanced Grant to maximize the use of the first clinically viable MYC inhibitor.
This ERC funding program is amongst the EU’s most prestigious and competitive, providing leading senior researchers with the opportunity to pursue ambitious, curiosity-driven projects that could lead to major scientific breakthroughs. The new grants, worth in total nearly €652 million, are part of the EU’s Horizon Europe programme. Only about fourteen per cent of per cent of ERC applicants are awarded these grants.
Bringing the first MYC inhibitor closer to the clinic
MYC is a multipurpose oncogene found deregulated in most human cancers. In normal cells, this transcription factor is tightly regulated and plays a pivotal role in a variety of cellular processes including cell growth, division and metabolism. However, the overexpression of MYC in cancer cells enables tumors to grow, thrive and resist anti-cancer therapies. Due to MYC’s undisputed role as a master regulator of intra- and extracellular factors of tumorigenesis, it has long been one of the most sought-after drug targets in cancer. Nevertheless, no MYC inhibitor has yet reached clinical approval.
Directed by Laura Soucek, two decades of research aimed at therapeutically targeting the “undruggable” MYC led to the in-house development of the Omomyc (OMO-103), the first MYC-inhibiting mini-protein to have successfully completed a phase Ia clinical trial. Based on this success, a phase Ib trial is currently underway to evaluate OMO-103 as first-line treatment combined with standard of care chemotherapy in patients with metastatic pancreatic cancer. This study is led by Teresa Macarulla, Head of VHIO’s Upper Gastrointestinal and Endocrine Tumors Group.
“Supported by this ERC Advanced Grant, the overarching goal of our MYCiMAX project is to maximize the use of this compound, as both a therapeutic and study tool, and open new lines of research to decipher different aspects of MYC biology,” says Laura Soucek.
Delving into MYC biology and exploring the translational applicability of Omomyc in different clinical cancer settings
One key objective of MYCiMAX is to identify a means for Omomyc to efficiently cross the blood-brain barrier for the treatment of patients with glioblastoma and/or brain metastases. The Soucek lab will also evaluate the combination of Omomyc with other targeted therapies, such as PARP and KRAS inhibitors, toward better understanding the role of MYC in DNA damage response (DDR) as well as the molecular mechanisms governing oncogenic crosstalk. Laura’s team will also seek to characterize subtypes of small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) with specific molecular characteristics that could also benefit from treatment with Omomyc.
“The main objectives of this project are to explore new aspects of MCY biology, trace new lines of research into the most deregulated oncogene in human tumors, as well as establish the immediate translational applicability of Omomyc in future clinical trials,” concludes Soucek.
Announced today, the ERC has named the 255 outstanding research leaders in Europe who have been awarded with ERC Advanced Grants: https://erc.europa.eu/sites/default/files/2024-04/erc-2023-adg-results-all-domains.pdf.
###
About the ERC
The ERC, set up by the European Union in 2007, is the premier European funding organisation for excellent frontier research. It funds creative researchers of any nationality and age, to run projects based across Europe. The ERC offers four core grant schemes: Starting Grants, Consolidator Grants, Advanced Grants and Synergy Grants. With its additional Proof of Concept Grant scheme, the ERC helps grantees to bridge the gap between their pioneering research and early phases of its commercialisation. The ERC is led by an independent governing body, the Scientific Council. Since November 2021, Maria Leptin is the President of the ERC. The overall ERC budget from 2021 to 2027 is more than €16 billion, as part of the Horizon Europe programme, under the responsibility of the European Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel.
About VHIO
The Vall d’Hebron Institute of Oncology (VHIO), established in 2006 and located within the Vall d’Hebron Campus, is a reference comprehensive cancer center for personalized medicine in oncology. Through our purely translational and multidisciplinary research model, we aim to improve the prevention, early diagnosis and treatment of cancer by transforming the latest scientific discoveries made in the laboratory into early phase clinical trials for the development of more effective therapies to improve the quality of life and survival of cancer patients.
VHIO forms part of the CERCA – Research Centres of Catalonia system and is accredited as a Severo Ochoa Center of Excellence.
Research at VHIO would not be possible without the support received from our patrons - Generalitat de Catalunya, Fundació Privada CELLEX, "La Caixa" Foundation, Fundación FERO, and the Fundación BBVA, the public funding it receives as well as the generous support from institutional supporters, private institutions, companies, associations, societies, and individual donors. Only with such continued support will VHIO continue to advance personalized and targeted therapies against cancer.
END
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology. An early phase randomized clinical trial involving 130 patients with sickle cell disease found that the drug, called riociguat, was found to be safe to use and well tolerated in these patients and significantly improved their blood pressure. Preliminary efficacy data suggested the medication might improve heart function.
An estimated 100,000 Americans ...
B-Cubed’s Hackathon – “Hacking Biodiversity Data Cubes for Policy” – concluded successfully on 5 April in Brussels. The event marked a significant milestone in the use of data cubes for enhancing biodiversity data analysis and policy-making. Over four days, participants from diverse backgrounds collaborated to explore innovative solutions aimed at standardising and improving the accessibility of biodiversity data.
The event began with a foundational presentation on data cubes by Andrew Rodrigues ...
Rutgers Health researchers have found that hypertensive disorders in pregnancy are strongly associated with fatal cardiovascular disease for up to a year after birth.
Among the hypertensive disorders that cause dangerously high blood pressure during pregnancy — chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia and eclampsia — all but gestational diabetes were associated with a doubling in the risk of fatal cardiovascular disease compared to women with normal blood pressure.
Eclampsia, a condition whereby hypertensive ...
Severe sepsis from bacterial or viral infections can be life-threatening and even people recovering from severe sepsis may experience long-lasting effects on the immune system, making them more susceptible to recurrent infections. The causes for this sepsis-induced immune suppression are not well understood and lack an effective treatment. To better understand the cause, Katherine MacNamara and colleagues from Albany Medical College, USA, analyzed the blood stem cells of mice with prior sepsis and their results were recently published in the journal Stem Cell Reports.
During ...
Concurrent occurrences of heatwaves and extreme short-term sea level rises at the same coastal locations significantly increased between 1998 and 2017 when compared to the preceding twenty years, reports a study published in Communications Earth & Environment. The study also suggests that these events may be five times more likely to occur between 2025 and 2049 under a modelled high emissions scenario.
A so-called ‘concurrent heatwave and extreme sea level’ (CHWESL) event is when a heatwave and an extreme short-term sea level rise occur at the same coastal location over the same time period. Although they ...
About The Study: The results of this study suggest that young breast cancer survivors without a germline pathogenic variant have a low risk of developing a second primary breast cancer in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.
Authors: Kristen D. Brantley, Ph.D., M.P.H., of the Harvard T. H. Chan School of Public Health in Boston, is the corresponding author.
To access ...
About The Study: In this study that included 1,470 adults with chronic low back pain, physician empathy was associated with better outcomes over 12 months. Greater efforts to cultivate and improve physician empathy appear warranted.
Authors: John C. Licciardone, D.O., M.S., M.B.A., of the University of North Texas Health Science Center at Fort Worth, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.6026)
Editor’s ...
Parasites thought only to infect tropical coral reefs have been discovered in a large variety of creatures in cold marine ecosystems along the Northeast Pacific, according to new research from University of British Columbia botanists.
The finding, published today in Current Biology, greatly expands the range of corallicolids, suggesting the parasites infect a range of organisms related to coral, like sea anemones and other cold-water marine invertebrates, around the world.
“This highlights significant blind spots in our strategies designed to sample microbial biodiversity,” says University of British Columbia biodiversity researcher Dr. Patrick Keeling, senior author on the ...
Researchers from Tokyo Medical and Dental University (TMDU) have developed a murine model for a highly progressive disease called “anti-MDA5 antibody-positive dermatomyositis”, providing insights into underlying biological mechanisms and aiding treatment
Tokyo, Japan – Some diseases involve autoimmune reactions, when the body begins to attack its own cells and proteins. The biological mechanisms underlying these diseases are often unknown, making treatment challenging. Now, a group at TMDU has created a murine model for a disease ...
Researchers have unveiled a microfluidic device that significantly improves the separation of tumor cells and clusters from malignant effusions. This novel technology promises to advance the diagnosis and treatment monitoring of cancer by enabling the high-throughput, continuous-flow ternary separation of single tumor cells, tumor cell clusters, and white blood cells (WBCs) from clinical pleural or abdominal effusions.
Understanding the nature of malignant effusions, teeming with tumor cells and clusters, is critical in comprehending the breadth of cancer's impact. The significant role of tumor clusters, with their heightened potential ...
